279 related articles for article (PubMed ID: 27845762)
1. Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4.
Patra MC; Choi S
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845762
[TBL] [Abstract][Full Text] [Related]
2. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
Seganish WM
Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of human IRAK1.
Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
[TBL] [Abstract][Full Text] [Related]
5. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
McElroy WT
Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
Genung NE; Guckian KM
Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
[TBL] [Abstract][Full Text] [Related]
8. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
Chaudhary D; Robinson S; Romero DL
J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
[TBL] [Abstract][Full Text] [Related]
10. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).
Wang L; Ferrao R; Li Q; Hatcher JM; Choi HG; Buhrlage SJ; Gray NS; Wu H
J Biol Chem; 2019 Mar; 294(12):4511-4519. PubMed ID: 30679311
[TBL] [Abstract][Full Text] [Related]
11. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
[TBL] [Abstract][Full Text] [Related]
12. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
Li X
Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
[TBL] [Abstract][Full Text] [Related]
13. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.
Murphy M; Pattabiraman G; Manavalan TT; Medvedev AE
Eur J Immunol; 2017 May; 47(5):880-891. PubMed ID: 28295231
[TBL] [Abstract][Full Text] [Related]
14. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
15. IRAK-4 inhibitors for inflammation.
Wang Z; Wesche H; Stevens T; Walker N; Yeh WC
Curr Top Med Chem; 2009; 9(8):724-37. PubMed ID: 19689377
[TBL] [Abstract][Full Text] [Related]
16. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
[TBL] [Abstract][Full Text] [Related]
17. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
[TBL] [Abstract][Full Text] [Related]
18. IRAK Inhibitor Protects the Intestinal Tract of Necrotizing Enterocolitis by Inhibiting the Toll-Like Receptor (TLR) Inflammatory Signaling Pathway in Rats.
Hou Y; Lu X; Zhang Y
Med Sci Monit; 2018 May; 24():3366-3373. PubMed ID: 29784900
[TBL] [Abstract][Full Text] [Related]
19. Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations.
Kuglstatter A; Villaseñor AG; Shaw D; Lee SW; Tsing S; Niu L; Song KW; Barnett JW; Browner MF
J Immunol; 2007 Mar; 178(5):2641-5. PubMed ID: 17312103
[TBL] [Abstract][Full Text] [Related]
20. A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.
Dou H; Song Y; Liu X; Yang L; Jiang N; Chen D; Li E; Tan R; Hou Y
Am J Respir Cell Mol Biol; 2014 Aug; 51(2):191-200. PubMed ID: 24588661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
